Quick Search (by title or disease)

Go to Advanced Search for more options.

Clinical Trials Help

Contact our Cancer Information Line nurse with your questions about open or upcoming clinical trials, second opinions, or patient referrals.
ccinfo@umn.edu • 612-624-2620 • 1-888-226-2376

Breast cancer Clinical Trials

Protocol Number Title
Methodology and Development of Tobacco Related Biomarkers Methodology and Development of Tobacco Related Biomarkers, part of 'Metabolism of Carcinogenic Tobacco-Specific Nitrosamines'
Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis (ISPY2)
2009UC147: SURMOUNT: Surveillance Markers of Utility for Recurrence after Neoadjuvant Therapy for Breast Cancer (Supplement 3 Sub-study to ISPY2)
Evaluating the Effectiveness of Reduced Nicotine Cigarettes, part of "Evaluating New Nicotine Standards for Cigarettes"
Vascular Assessment in Breast Cancer Survivors Taking Aromatase Inhibitors
A Device to Quantify Sweat of Single Sweat Glands to Diagnose Neuropathy
Mobile Phone Multimedia Messaging Intervention for Breast Cancer Screening: Intervention Phase
Quantitative Methods for Supplementing Contrast-Enhanced Magnetic Resonance Imaging of Breast Cancer.
Millenium C31001: A phase 1b/2 study of safety and efficacy of MLN0128 (Dual TORC 1/2 Inhibitor) in combination with exemestane or fulvestrant therapy in postmenopausal women with ER+/HER2- advanced or metastatic breast cancer that has progressed on treatment with everolimus in combination with exemestane or fulvestrant
Pilot Study of Clone 6 scFv As a Novel Marker for Isolation and Characterization of Circulating Tumor Cells (CTCs) in Metastatic Breast Cancer and Bladder Cancer
Phase III Study Evaluating Palbociclib (PD-0332991), a Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor in Patients with Hormone Receptor Positive, HER2-normal Primary Breast Cancer with High Relapse Risk after Neoadjuvant Chemotherapy (Penelope)
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Aromatase Inhibitors and Vascular Health
An open label, phase Ib, dose-escalation study evaluating the safety and tolerability of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours and in combination with endocrine therapy in patients with locally advanced or metastatic hormone receptor-positive, HER2-, breast cancer, followed by expansion cohorts
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB057643 in Subjects with Advanced Malignancies
A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-016
EAY131-Z1C: MATCH Treatment Subprotocol Z1C: Phase II Study of Palbociclib (PD-0332991) in Patients with Tumors with CDK4 or CDK6 Amplification and Rb Protein Expression by IHC

17 trials displayed